CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLYM CLIMB BIO INC

交易中 07-15 15:15:11 EDT

13.65

+0.41

+3.10%

最高13.99	最低12.75	成交量62.48万
今开13.14	昨收13.24	日振幅9.37%
总市值7.82亿	流通市值5.66亿	总股本5,726万
成交额853.85万	换手率1.51%	流通股本4,143万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":13.65,"timestamp":1784142906693,"preClose":13.24,"halted":0,"volume":624821,"delay":0,"changeRate":0.030966767371601218,"floatShares":41430600,"shares":57260500,"eps":-0.789373,"marketStatus":"交易中","change":0.41,"latestTime":"07-15 15:15:11 EDT","open":13.14,"high":13.99,"low":12.75,"amount":8538455.760703,"amplitude":0.093656,"askPrice":13.72,"askSize":45,"bidPrice":13.64,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.789373,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784145600000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":13.24,"preHourTrading":{"tag":"盘前","latestPrice":13.24,"preClose":13.24,"latestTime":"09:25 EDT","volume":38,"amount":503.30000600000005,"timestamp":1784121900086,"change":0,"changeRate":0,"amplitude":0.000755},"postHourTrading":{"tag":"盘后","latestPrice":13.24,"preClose":13.24,"latestTime":"19:51 EDT","volume":9445,"amount":125038.1904,"timestamp":1784073082933,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.58668,"impliedVol":0.7318,"impliedVolPercentile":0.1833},"requestUrl":"/m/hq/s/CLYM","defaultTab":"news","newsList":[{"id":"1139596781","title":"Climb Bio公布SEC文件：Clym116一期临床未现严重不良事件或剂量限制性毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1139596781","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139596781?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:15","pubTimestamp":1780658117,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，生物制药公司Climb Bio Inc.宣布，其候选药物Clym116在一期临床试验中展现出良好的安全性特征。数据显示，试验期间未观察到任何严重不良事件（SAEs）或剂量限制性毒性（DLTs）。这一积极结果标志着该药物早期开发阶段的一个重要里程碑，为后续研究的推进奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178148202","title":"Climb Bio提交SEC文件：现有股东拟转售最多1160万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1178148202","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178148202?lang=zh_cn&edition=full","pubTime":"2026-05-30 04:08","pubTimestamp":1780085294,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件显示，Climb Bio Inc. 已登记由售股股东进行的普通股转售，涉及股份数量最高可达1160万股。此次提交意味着相关股东已获得在未来公开市场出售这部分股份的资格，但具体出售的时间、价格及数量将由股东自行决定。公司本身不会从此次售股中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114292362","title":"CLIMB BIO INC宣布完成1.1亿美元私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1114292362","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114292362?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:04","pubTimestamp":1777374278,"startTime":"0","endTime":"0","summary":"马萨诸塞州韦尔斯利山——临床阶段生物技术公司CLIMB BIO INC于今日宣布，已与特定机构合格投资者签署证券购买协议，通过私募配售募集资金总额约1.1亿美元。根据协议，公司将以每股9.50美元的价格发行总计948.1万股普通股；同时向部分投资者发行预融资认股权证，每份认股权证价格9.4999美元，可认购210.6万股普通股。每份认股权证行权价为0.0001美元，在遵守持有人持股比例限制的前提下可立即行权，有效期至全额行权完毕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170647334","title":"Climb Bio宣布FDA授予布多普鲁替格治疗原发性膜性肾病快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1170647334","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170647334?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:00","pubTimestamp":1775559642,"startTime":"0","endTime":"0","summary":"Climb Bio（股票代码：CLYM）今日宣布，美国食品药品监督管理局（FDA）已授予其候选药物布多普鲁替格（Budoprutug）快速通道资格，用于治疗原发性膜性肾病。\n这一认定将加速该药物的审评进程，为患者提供更早获得创新疗法的可能性。原发性膜性肾病是一种自身免疫性肾脏疾病，目前治疗选择有限。\n快速通道资格旨在促进针对严重疾病且未满足医疗需求药物的开发与审评。Climb Bio表示将继续推进布多普鲁替格的临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129822834","title":"CLIMB BIO INC：Susan Altschuller 将于2026年4月30日起担任首席会计官","url":"https://stock-news.laohu8.com/highlight/detail?id=1129822834","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129822834?lang=zh_cn&edition=full","pubTime":"2026-04-04 04:27","pubTimestamp":1775248033,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会（SEC）的文件，生物科技公司 CLIMB BIO INC 宣布，Susan Altschuller 将于2026年4月30日正式出任公司首席会计官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117014745","title":"CLIMB BIO INC：Budoprutug Prismn二期PMN试验完成首例患者给药，初步数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1117014745","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117014745?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:04","pubTimestamp":1767873896,"startTime":"0","endTime":"0","summary":"CLIMB BIO INC宣布，其针对PMN（进行性多发性神经病）的Budoprutug Prismn二期临床试验已完成首例患者给药。该试验旨在评估候选药物的安全性与有效性，预计将于2026年下半年获得初步研究数据。这一里程碑标志着公司在神经疾病治疗领域的研发推进取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601186879","title":"Climb Bio, Inc.盘中异动 早盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186879?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:04","pubTimestamp":1767625482,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日23时04分，Climb Bio, Inc.股票出现异动，股价大幅跳水5.07%。截至发稿，该股报3.56美元/股，成交量16.0404万股，换手率0.24%，振幅7.15%。Climb Bio, Inc.股票所在的生物技术行业中，整体跌幅为1.48%。Climb Bio, Inc.公司简介：Climb Bio Inc是一家临床阶段的生物技术公司，为免疫介导性疾病患者开发治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105230442953c04f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105230442953c04f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484991306","title":"Climb Bio, Inc.2024财年第三财季实现净利润-8.90百万美元，同比减少124.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484991306?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010429,"startTime":"0","endTime":"0","summary":"11月19日，Climb Bio, Inc.公布财报，公告显示公司2024财年第三财季净利润为-8.90百万美元，同比减少124.18%；其中营业收入为0.00美元，每股基本收益为-0.13美元。从资产负债表来看，Climb Bio, Inc.总负债3.42百万美元，其中短期债务58000.00美元，资产负债比为0.65，流动比率为0.58。机构评级：截至2024年11月19日，当前有2家机构对Climb Bio, Inc.目标价做出预测，其中目标均价为4.50美元，其中最低目标价为4.00美元，最高目标价为5.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180146a24562b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180146a24562b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":0.1573},{"period":"3month","weight":0.5306},{"period":"6month","weight":2.5119},{"period":"1year","weight":8.3239},{"period":"ytd","weight":2.31}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Climb Bio, Inc.于2018年10月18日作为特拉华州公司注册成立。该公司是一家生物技术公司，专注于开发神经元兴奋性障碍的新疗法，以解决精神病学、癫痫、慢性疼痛以及外周和中枢神经系统疾病方面未满足的需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.088588},{"month":3,"riseRate":0.2,"avgChangeRate":-0.090224},{"month":4,"riseRate":0.8,"avgChangeRate":0.28834},{"month":5,"riseRate":0.6,"avgChangeRate":0.068848},{"month":6,"riseRate":0.4,"avgChangeRate":-0.017955},{"month":7,"riseRate":0.8,"avgChangeRate":0.064091},{"month":8,"riseRate":0.25,"avgChangeRate":0.096778},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CLIMB BIO INC(CLYM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CLIMB BIO INC(CLYM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}